e-ISSN 2329-0072




Get your full text copy in PDF

CA 242 and p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma

Bettina Genz, Matthias Lorenz, Hildegund Sauer-Eppel, Gerhard M Oremek

Med Sci Tech 2007; 48(2): RA97-99

ID: 881551

Introduction: In human pancreatic carcinoma (PCa) mutations in the p53 tumour suppressor gene are present in up to 50% of cases. Conformational change and cellular accumulation, together with subsequent release of mutant and normal p53 protein from transformed cells, may initiate a B-cell response with generation of circulating autoantibodies to p53 protein (anti-p53). Material and Methods: In the present study we analyzed the sera of 85 consecutive patients with acute pancreatitis (n=19), chronic pancreatitis (n=33) and PCa (n=33) to evaluate the specificity of autoantibodies to p53 protein (anti-p53) as a serological marker for PCa. Detection of anti-p53 was performed using an ELISA system with immobilized recombinant wild-type p53 protein.Quatitative determination of CA-242 was performed by an enzyme- immunological assay. Results: Autoantibodies to p53 were detectable in 1/19 patients with acute (5.3%) and in 4/33 patients with chronic pancreatitis (12.1%). All anti-p53 positive patients with acute or chronic pancreatitis were carefully examined and no underlying malignant disease was found. During follow-up (range: 281 – 647 days; mean: 472 days) none of these patients showed any evidence for subsequent development of PCa or any other malignantndisease. In patients with PCa and anti-p53 was detected in 6/33 cases resulting in a sensitivity of 18.2% with a specificity of 90.4%. In contrast to anti-p53, detection of serum carbohydrate antigen (CA 242) resulted in a sensitivity and specificity 65.7% and 79.2% (CA 242 <27 U/ml) and 79.2% and 90.4% (Ca 242 >100 U/ml) for the detection of PCa, respectively. Taken together, the sensitivity of anti-p53 formation was low in patients with PCa (18.2%). Conclusions: Futhermore, the detection of anti-p53 was not specific for malignancy indicating that severe inflammatory processes may also induce anti-p53 formation.The sensitivity and specificity of the tumour marker CA 242 for the detection of pancreatic cancer was respectively. (Clin Exp Med Lett 2007; 48(2): 97-99)

Keywords: anti-p53, Autoantibodies, pancreatic carcinoma, acute pancreatitis, chronic pancreatitis, tumour screening

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree